Fox Business - The Power to Prosper
Search Site

Baxter International

Investing lessons from the biotech rout

The Healthcare Model on Covestor had a challenging month in March and into early April, 2014.  As of April 3, 2014, the model while down 6.3% for the prior 30 days. Over a 90-day period, the portfolio is up 11% and, on a  trailing 365 day basis, it's up 44.3% as of April 3, 2014.This portfolio had a good ride with some of the bigger biotech names like Alexion ( ALXN ), Celgene ( CELG ), Biogen Idec ( BIIB ), Illumina ( ILMN ), and Gilead ( GILD ).  Recent biotech purchases like Vanda ( VNDA ), Salix ( SLXP ) also came under intense selling pressure during the month’s now infamous biotech rout .This month tested my manager skills. With some of my top stocks declining, should I stay put or move aside?  Like the Wisconsin Badger’s Frank Kaminsky who learned to pivot to help get his team to the quarter-finals of the NCAA March Madness basketball tournament, I also tried to employ the Wisconsin ‘pivot’ in investing.My first instinct as my leading holdings started breaking down was to sell a...

Read More

  1. Medical Device Tax Has Got to Go

    Just how bad is a tax that treats pacemakers and CT scan machines as if they're alcohol or cigarettes?Last January 1, medical-device makers had to start paying a new...

  2. Why I sold Baxter and CareFusion

    The Covestor Healthcare portfolio that I manage did not escape the effects of the August sell-off which resulted in a 3.5% loss for the S&P 500 Index (SPX), the bigg...

  3. Aveo: Anatomy of a trade gone wrong

    Riding on the back of a strong market, the TenStocks portfolio racked up decent year-to-date gains coming into late April. As qualifying investments became harder to...

  4. Postgame Wrap-Up: 7/18/13

    TV's Andy Levy puts the 'ombudsman' in 'Red Eye' ombudsman

  5. The Trends to Watch in Pharma

    Gabelli Funds Portfolio Manager Jeff Jonas on the pharmaceutical sector stocks to watch in the second half of 2012.

  6. Microsoft to Update Windows 8

    FBN’s Adam Shapiro on Microsoft’s plans to update its latest operating system.

  7. Baxter's Potential Alzheimer's Treatment Immunoglobulin Misses Primary Endpoints

    Baxter International Inc. (BAX) said results from a late-stage study of its potential treatment for Alzheimer's, immunoglobulin, were negative.The results didn't mee...

  8. Health-Care Companies Report Slowdown in Patient Visits

    The spike late last year in doctor and hospital visits apparently lasted as long as the flu.After years of decelerating health-care usage--linked to economic problem...

  9. Baxter's Sales Rise, But Health-Care Pressures Remain

    Baxter International Inc. (BAX) reported a slight increase in first-quarter sales, as growth in emerging markets helped to offset continued pricing and utilization p...

  10. Report: More Than 160 Injured in Texas Explosion

    FBN’s Diane Macedo breaks down the stories moving the markets around the world.

  11. Baxter 1st-Quarter Profit Off 11% on Acquisition-Related Charges

    Baxter International Inc.'s (BAX) first-quarter earnings fell 11% as the medical-products company was hurt by acquisition-related charges and the year-earlier period...

  12. Market Wrap for Friday, March 22: Stocks Rise on Hopes of Bailout Deal for Cyprus

    The U.S. stock market closed out a choppy week with a gain as policymakers in Cyprus were in talks with EU officials to secure a bailout for the Mediterranean island...

  1. Baxter to Split Itself into Two Companies

    Baxter International (NYSE:BAX) unveiled plans on Thursday to split itself into two separate companies, creating an independent biopharmaceuticals firm.A second comp...

  2. Merck Snags Baxter Executive As CFO

    Merck (NYSE:MRK) tapped Baxter (NYSE:BAX) executive Robert Davis on Thursday to replace current finance head Peter Kellogg as the company struggles to revive sales a...

  3. Baxter International 4Q earnings

    Earnings HQ: FBN’s Diane Macedo breaks down Baxter International ’s fourth-quarter earnings report.

  4. Previewing day two of the 2014 World Economic Forum

    FBN’s Liz Claman’s interviews include Muhtar Kent, John Chambers, Howard Lutnick, Michael Corbat and Bob Greifeld.

  5. Baxter to Develop Gene Fighter to Treat Leukemia

    Drug giant Baxter International (NYSE:BAX) inked a licensing partnership with smaller rival Cell Therapeutics (NYSE:CTI) on Friday to develop and commercialize a gen...

  6. Strategies for investors to profit in this market

    Huntington Funds CIO Randy Bateman on stocks to boost investors’ portfolios.

  7. 7 Jobs that Require Great Credit

    You've shined your shoes, know where you see yourself in five years and boned up on the firm's bigwigs. Before applying for that dream -- or even interim -- job, you...

‹ Prev12345Next ›
Freebase CC-BY
Source: Baxter International on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL